AMRX

$20.21-1.13%visit website

Amneal Pharmaceuticals, Inc.

Market Cap

$6.5B

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.23

60mo monthly vs SPY

P/E (TTM)

42.1

TTM to Jun 2026 · diluted EPS

P/S (TTM)

2.1

TTM to Jun 2026 · revenue

P/B

195.4

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	784,513	814,319	722,519	796,197	3,117,548
Cost of revenue	510,539	517,129	402,406	461,689	1,891,763
Gross profit	273,974	297,190	320,113	334,508	1,225,785
Research & development	63,352	34,819	38,383	39,017	175,571
Selling, general & administrative	137,815	146,458	138,860	148,722	571,855
Operating income	70,344	112,033	141,772	129,769	453,918
Pretax income	(5,223)	55,235	80,176	70,990	201,178
Income tax	(23,355)	5,662	2,176	1,376	(14,141)
Net income	2,369	35,076	62,256	57,662	157,363
EPS (basic) ($)	0.01		0.20	0.18	0.50
EPS (diluted) ($)	0.01		0.19	0.18	0.48
Weighted avg. shares (basic)	314,168		316,023	319,200
Weighted avg. shares (diluted)	324,754		328,933	328,102

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 34 more quarters, back to Mar 2017, with Tormere Pro.

Corporate Events (8-K)

1 filing in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Nov 3, 2026 accepted 8:07 AM ET	2.02Earnings release7.01Reg FD disclosure	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

69%

W/W -6.2pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

82.82x

Avg Daily Selling (90d)

4,589 sh/day

Baseline Daily Selling

142 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-13	2026-08-14	Kiely John	Director	Sale	50.0K	$17.64	$882K	210.3K	View
2026-08-12	2026-08-13	Shah Nikita	Executive Vice President	Sale	146.4K	$17.51	$2.56M	253.4K	View
2026-08-12	2026-08-13	Daly Jason B.	EVP, Chief Legal Officer	Sale	210.0K	$17.40	$3.65M	35.2K	View
2026-08-11	2026-08-13	Daly Jason B.	EVP, Chief Legal Officer	Sale	6,613	$17.70	$117K	245.2K	View
2026-05-11	2026-05-12	Autor Deborah M.	Director	Sale	34.8K	$12.94	$451K	93.7K	View

Recent News

Will Raised 2026 Guidance Change Amneal Stock Narrative

Simply Wall St · 2026-11-04

Amneal Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Yahoo Finance · 2026-11-04

What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call

Yahoo · 2026-11-03

NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View

Yahoo · 2026-11-03

JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View

Yahoo · 2026-11-03

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Yahoo · 2026-11-03

CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

Yahoo · 2026-11-03

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript

SeekingAlpha · 2026-11-03

Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say

Yahoo · 2026-11-03

Amneal Pharmaceuticals (NASDAQ:AMRX) Beats Q3 Estimates but Cash-Flow Guidance Weighs on Shares

ChartMill · 2026-11-03

Amneal (NASDAQ:AMRX) beats expectations in strong Q3 2026, full-year outlook slightly exceeds expectations

Yahoo · 2026-11-03

Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates

Yahoo · 2026-11-03

Amneal Reports Third Quarter 2026 Financial Results

Yahoo · 2026-11-03

Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript

Benzinga · 2026-11-03

Amneal Pharmaceuticals (AMRX) Stock Looks Fully Valued After A 3 Year Rally

Simply Wall St · 2026-11-03

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-08-13	Kiely John	S	50,000	$882,000
2026-08-12	Shah Nikita	S	146,403	$3M
2026-08-12	Daly Jason B.	S	210,000	$4M
2026-08-11	Daly Jason B.	S	6,613	$117,050.1
2026-05-11	Autor Deborah M.	S	34,819	$450,557.86

AMRX

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

Amneal Pharmaceuticals, Inc. (AMRX)

Reporting Insiders

Factor Profile

Corporate Events (8-K)